Norinchukin Bank The Has $52.77 Million Stake in Zoetis Inc. $ZTS

Norinchukin Bank The boosted its position in Zoetis Inc. (NYSE:ZTS) by 12.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 360,648 shares of the company’s stock after purchasing an additional 38,554 shares during the period. Zoetis accounts for about 0.7% of Norinchukin Bank The’s portfolio, making the stock its 23rd biggest holding. Norinchukin Bank The owned about 0.08% of Zoetis worth $52,770,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV boosted its position in Zoetis by 38.9% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 62,560 shares of the company’s stock worth $9,154,000 after buying an additional 17,536 shares during the period. Moneta Group Investment Advisors LLC raised its stake in shares of Zoetis by 14.0% during the third quarter. Moneta Group Investment Advisors LLC now owns 5,927 shares of the company’s stock valued at $867,000 after acquiring an additional 730 shares during the last quarter. L2 Asset Management LLC lifted its holdings in shares of Zoetis by 11.6% during the third quarter. L2 Asset Management LLC now owns 2,045 shares of the company’s stock worth $299,000 after purchasing an additional 213 shares during the period. Lido Advisors LLC lifted its holdings in shares of Zoetis by 25.2% during the third quarter. Lido Advisors LLC now owns 47,420 shares of the company’s stock worth $6,940,000 after purchasing an additional 9,531 shares during the period. Finally, Gotham Asset Management LLC grew its stake in shares of Zoetis by 33.0% in the third quarter. Gotham Asset Management LLC now owns 74,801 shares of the company’s stock worth $10,945,000 after purchasing an additional 18,574 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $118.20 on Tuesday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm’s fifty day simple moving average is $125.12 and its two-hundred day simple moving average is $131.33. Zoetis Inc. has a 12 month low of $114.47 and a 12 month high of $172.23. The stock has a market capitalization of $49.90 billion, a P/E ratio of 19.63, a price-to-earnings-growth ratio of 1.76 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the previous year, the business earned $1.40 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZTS. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Stifel Nicolaus lowered their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Bank of America lifted their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Finally, UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.